-
OlympiA
GLOBAL This trial is a collaborative study with BIG.
A randomised, double-blind, parallel group, placebo-controlled multicentre Phase III study to assess the efficacy and safety of olaparib versus placebo as adjuvant treatment
- Status
- No Longer Recruiting
- Objectives
- A randomised, double-blind, parallel group, placebo-controlled multicentre Phase III study to assess the efficacy and safety of olaparib versus placebo as adjuvant treatment in patients with germline BRCA1/2 mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy
- Subjects
- Endpoints
- (1)IDFS (2)OS, DDFS, etc
- Trial Period
- Apr.,2014 to Feb.,2028
- Lead Principal Investigator
- Prof.Andrew Tutt (King's College, London School of Medicine)
- Target Sample Size
- 144 Domestic / 1800 International
- Regimen
- Olaparib vs Placebo
- Source of Funding
- AstraZeneca K.K.
- Conference Presentation
- Articles and Publications
- Memo
- COI Disclosure